Fresenius Medical Care AG & Co. (FMS) Given “Hold” Rating at Royal Bank of Canada

Fresenius Medical Care AG & Co. (FMS) Given “Hold” Rating at Royal Bank of Canada

A number of other equities research analysts have also recently issued reports on the company. DZ Bank AG reaffirmed a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday. Zacks Investment Research cut Fresenius Medical Care AG & Co. from a buy rating to a hold rating in a research report on Friday, May 5th. Sanford C. Bernstein reaffirmed a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Sunday, March 12th. Finally, Societe Generale cut Fresenius Medical Care AG & Co. from a buy rating to a hold rating in a research report on Friday, February 24th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Fresenius Medical Care AG & Co. presently has an average rating of Buy and a consensus target price of $47.00.

Royal Bank of Canada reissued their hold rating on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) in a research note released on Tuesday. They currently have a $44.00 target price on the stock.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 3.2363% on Tuesday, reaching $47.8397. 81,815 shares of the company’s stock were exchanged. The firm’s 50 day moving average price is $44.99 and its 200-day moving average price is $42.02. The company has a market capitalization of $29.31 billion, a P/E ratio of 21.0238 and a beta of 0.53. Fresenius Medical Care AG & Co. has a 12 month low of $38.05 and a 12 month high of $47.93.

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its earnings results on Wednesday, May 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.09. The firm had revenue of $4.55 billion during the quarter, compared to analysts’ expectations of $4.69 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.56% and a net margin of 6.67%. During the same quarter in the prior year, the business earned $0.75 earnings per share. On average, equities analysts anticipate that Fresenius Medical Care AG & Co. will post $2.24 EPS for the current year.

The business also recently announced an annual dividend, which was paid on Friday, May 26th. Shareholders of record on Monday, May 15th were given a dividend of $0.5137 per share. The ex-dividend date of this dividend was Thursday, May 11th. This represents a yield of 1.17%. Fresenius Medical Care AG & Co.’s payout ratio is currently 16.23%.

A number of large investors have recently made changes to their positions in FMS. Goldman Sachs Group Inc. boosted its stake in shares of Fresenius Medical Care AG & Co. by 4.8% in the first quarter. Goldman Sachs Group Inc. now owns 204,051 shares of the company’s stock worth $8,597,000 after buying an additional 9,403 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Fresenius Medical Care AG & Co. by 18.2% in the first quarter. HighTower Advisors LLC now owns 24,638 shares of the company’s stock worth $1,041,000 after buying an additional 3,801 shares during the last quarter. Level Four Advisory Services LLC boosted its stake in shares of Fresenius Medical Care AG & Co. by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock worth $478,000 after buying an additional 58 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Fresenius Medical Care AG & Co. by 12.1% in the first quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock worth $62,917,000 after buying an additional 161,262 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. during the first quarter worth about $3,219,000. 2.52% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “FMS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment